Evidence map›Paper›PMID 42127027›Full record

Observational studyVirulence2026

Multicenter retrospective observational study on the clinical effectiveness of butyrate-producing

Yoshihiko Morikawa, Hideo Kato, Takumi Umemura, Jun Hirai, Yuichi Shibata, Mao Hagihara, Nobuhiro Asai, Hiroshige Mikamo, Takuya Iwamoto

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Virulence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoshihiko MorikawaDepartment of Pharmacy, Mie University Hospital, Mie, Japan.
Hideo KatoDepartment of Pharmacy, Mie University Hospital, Mie, Japan.ORCID 0000-0002-5272-9560
Takumi UmemuraDepartment of Pharmacy, Tosei General Hospital, Seto, Japan.
Jun HiraiDivision of Infection Control and Prevention, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan.
Yuichi ShibataDepartment of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Japan.
Mao HagiharaDepartment of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Japan.
Nobuhiro AsaiDepartment of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Japan.
Hiroshige MikamoDepartment of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Japan.
Takuya IwamotoDepartment of Pharmacy, Mie University Hospital, Mie, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Butyrate-producing bacteria, which are components of the gut microbiome, activate host defense mechanisms against several types of infections, including respiratory viral infections. However, the clinical effectiveness of butyrate-producing

Indexed as

ButyratesClostridium butyricumCOVID-19ProbioticsAgedFemaleHospital MortalityHumansMalePneumonia, BacterialRespiration, ArtificialRetrospective StudiesTreatment OutcomeButyratesbutyrate-producing bacteriaCOVID-19probioticssecondary bacterial pneumonia

Identifiers

PMID42127027
PMCPMC13182968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.